Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma

被引：19
作者：
van de Donk, Niels W. C. J. [1 ]
Casneuf, Tineke [2 ]
Di Cara, Alessandro [3 ]
Parren, Paul W. [4 ,5 ,6 ]
Zweegman, Sonja [1 ]
van Kessel, Berris [1 ]
Lokhorst, Henk M. [1 ]
Usmani, Saad Z. [7 ]
Lonial, Sagar [8 ]
Richardson, Paul G. [9 ]
Chiu, Christopher [10 ]
Mutis, Tuna [1 ]
Nijhof, Inger S. [1 ]
Sasser, A. Kate [10 ]
机构：
[1] Vrije Univ Amsterdam Med Ctr, Dept Haematol, Amsterdam, Netherlands
[2] Janssen Res & Dev, Beerse, Belgium
[3] Quartz Bio, Geneva, Switzerland
[4] Genmab, Utrecht, Netherlands
[5] Univ Southern Denmark, Dept Canc & Inflammat Res, Inst Mol Med, Odense, Denmark
[6] Leiden Univ, Med Ctr, Dept Immunohaematol & Blood Transfus, Leiden, Netherlands
[7] Carolinas Healthcare Syst, Levine Canc Inst, Charlotte, NC USA
[8] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA
[9] Harvard Med Sch, Jerome Lipper Myeloma Ctr, Dept Med Oncol, Dana Farber Canc Inst, Boston, MA USA
[10] Janssen Res & Dev, Spring House, PA USA
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2019年 / 184卷 / 03期
关键词：
multiple myeloma; daratumumab; Fc gamma receptors; immunotherapy; polymorphisms; NATURAL-KILLER-CELLS; TARGETING CD38; MONOTHERAPY; ANTIBODIES;
D O I：
10.1111/bjh.15122
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：475 / 479
页数：5
相关论文
共 50 条
  • [21] Efficacy and safety of daratumumab in the treatment of relapsed/refractory multiple myeloma: A meta-analysis of randomized controlled trials
    Huang, Zeng-Yi
    Jin, Xiao-Qin
    Liang, Qi-Lian
    Zhang, Ding-Yue
    Han, Han
    Wang, Zhen-Wei
    MEDICINE, 2023, 102 (38) : E35319
  • [22] Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma
    Hirohiko Shibayama
    Morio Matsumoto
    Hiroshi Kosugi
    Kazuhiro Shibayama
    Hiroshi Yamazaki
    Shinsuke Iida
    International Journal of Hematology, 2021, 113 : 112 - 121
  • [23] Daratumumab plus carfilzomib: An optimistic approach in relapsed/refractory multiple myeloma
    Dubey, A. P.
    Khatri, Sameer
    Maggo, Sachin
    Singh, Nilabh K.
    Sharma, Durgesh
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2020, 41 (06) : 846 - 849
  • [24] Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma
    Gueneau, Pauline
    Chretien, Marie-Lorraine
    Cransac-Miet, Amelie
    Aho, Ludwig Serge
    Lafon, Ingrid
    Favennec, Camille
    Guy, Julien
    Caillot, Denis
    Boulin, Mathieu
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (05) : 518 - 525
  • [25] Daratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study
    Sunami, Kazutaka
    Murakami, Hiroyuki
    Tagashira, Hisashi
    Ueda, Hiroko
    Moriyama, Takashi
    Ishikawa, Tatsunori
    Yoshioka, Takanori
    Makita, Masanori
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (12) : 2151 - 2157
  • [26] Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients
    Nooka, Ajay K.
    Joseph, Nisha S.
    Kaufman, Jonathan L.
    Heffner, Leonard T.
    Gupta, Vikas A.
    Gleason, Charise
    Boise, Lawrence H.
    Lonial, Sagar
    CANCER, 2019, 125 (17) : 2991 - 3000
  • [27] Real-world effectiveness and safety of daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma in Slovakia
    Harvanova, L'ubica
    Stulajterova, Viera
    Guman, Tomas
    Ladicka, Miriam
    Hlebaskova, Monika
    Chudej, Juraj
    Simek, Miroslav
    Stecova, Natalia
    Flochova, Emilia
    Kubala, Jan
    Simancikova, Iveta
    Drgona, L'ubos
    Vranovsky, Andrej
    Wild, Alexander
    Mistrik, Martin
    Batorova, Angelika
    NEOPLASMA, 2021, 68 (03) : 626 - 630
  • [28] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
    Chari, Ajai
    Suvannasankha, Attaya
    Fay, Joseph W.
    Arnulf, Bertrand
    Kaufman, Jonathan L.
    Ifthikharuddin, Jainulabdeen J.
    Weiss, Brendan M.
    Krishnan, Amrita
    Lentzsch, Suzanne
    Comenzo, Raymond
    Wang, Jianping
    Nottage, Kerri
    Chiu, Christopher
    Khokhar, Nushmia Z.
    Ahmadi, Tahamtan
    Lonial, Sagar
    BLOOD, 2017, 130 (08) : 974 - 981
  • [29] The safety of daratumumab for the treatment of multiple myeloma
    Cejalvo, Maria J.
    Ribas, Paz
    de la Rubia, Javier
    EXPERT OPINION ON DRUG SAFETY, 2017, 16 (06) : 753 - 760
  • [30] Role of daratumumab in relapsed or refractory multiple myeloma patient: A meta-analysis and literature to review
    Tauseef, Abubakar
    Zafar, Maryam
    Silberstein, Peter
    Nahas, Joseph
    Frederickson, Thomas
    Abodunrin, Faith
    Abbas, Anum
    Arshad, Wafa
    Lateef, Noman
    Rangoonwala, Hussain
    Albagoush, Sara
    Mirza, Mohsin
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2022, 11 (06) : 2648 - 2655
12345